Skip to Content
Merck
  • Blood pressure and cardiorenal responses to antihypertensive therapy in obese women.

Blood pressure and cardiorenal responses to antihypertensive therapy in obese women.

Arquivos brasileiros de endocrinologia e metabologia (2008-03-18)
Eduardo Cantoni Rosa, Maria Tereza Zanella, Nárcia Elisa Bellucci Kohlmann, Sandra Roberta Gouveia Ferreira, Frida Liane Plavnik, Artur Beltrame Ribeiro, Osvaldo Kohlmann
ABSTRACT

Blood pressure (BP) and target organ responses to antihypertensive drugs are not well established in hypertensive obese patients. This study is aimed at evaluating the effects of obesity and adiposity distribution patterns on these responses. 49 hypertensive obese women were designated to different groups according to waist to hip ratio measurements--37 with troncular and 12 with peripheral obesity. Patients were treated for 24-weeks on a stepwise regimen with cilazapril alone or a cilazapril/hydrochlorothiazide/amlodipine combination therapy to achieve a BP lower than 140/90 mmHg. Ambulatory blood pressure monitoring (ABPM), echocardiography, and albuminuria were assessed before and after the intervention. After 24 weeks, weight loss was less than 2% in both groups. ABPM targets were achieved in 81.5% of patients upon a combination of 2(26.5%) or 3(55.1%) drugs. Similar reductions in daytime-SBP/DBP: -22.5/-14.1(troncular obesity)/-23.6/-14.9 mmHg (peripheral obesity) were obtained. Decrease in nocturnal-SBP was greater in troncular obesity patients. Upon BP control, microalbuminuria was markedly decreased, while only slight decrease in left ventricular mass was observed for both groups. In the absence of weight loss, most patients required combined antihypertensive therapy to control their BP, regardless of their body fat distribution pattern. Optimal target BP and normal albuminuria were achieved in the group as a whole and in both obese patient groups, while benefits to cardiac structure were of a smaller magnitude.

MATERIALS
Product Number
Brand
Product Description

Cilazapril, European Pharmacopoeia (EP) Reference Standard
Cilazapril impurity D, European Pharmacopoeia (EP) Reference Standard